

# Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey's 4th Annual Orphan Drug Day

February 8, 2018

HAYWARD, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases, today announced its participation in the BIO CEO & Investor Conference (February 12<sup>th</sup>) and SunTrust Robinson Humphrey's 4<sup>th</sup> Annual Orphan Drug Day (February 13<sup>th</sup>).

Additional information on Anthera can be found at [www.anthera.com](http://www.anthera.com).

## About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases. Additional information on the Company can be found at [www.anthera.com](http://www.anthera.com).

## Safe Harbor Statement

*Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.*

## Contact Information

CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc.  
[ir@anthera.com](mailto:ir@anthera.com)

For Media Inquiries:  
Frannie Marmorstein  
rbb Communications  
[Frannie.marmorstein@rbbcommunications.com](mailto:Frannie.marmorstein@rbbcommunications.com)  
305-562-0542

[www.twitter.com/antherapharma](https://www.twitter.com/antherapharma)  
<https://www.facebook.com/antherapharma/>  
<https://www.linkedin.com/company/anthera-pharmaceuticals>

Source: Anthera Pharmaceuticals, Inc.

 Primary Logo

Source: Anthera Pharmaceuticals, Inc.